Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × Anticonvulsants × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis Complex-associated Refractory Seizures 1

Interventions

Carboplatin 33 Cisplatin 28 pembrolizumab 27 Paclitaxel 26 Pemetrexed 20 Gemcitabine 19 Nivolumab 18 Rituximab 15 Dexamethasone 15 Ipilimumab 12 Fluorouracil 11 Docetaxel 11 Cyclophosphamide 11 durvalumab 10 Lenalidomide 9 Capecitabine 9 Bevacizumab 9 olaparib 8 atezolizumab 8 Doxorubicin 8 Cytarabine 8 130-nm albumin-bound paclitaxel 8 daratumumab 7 Prednisone 7 Leucovorin 7 Etoposide 7 Bortezomib 7 venetoclax 6 osimertinib 6 Trastuzumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01713946 2018-11-07

EXIST-3

Novartis

Phase 3 Completed

366 enrolled 38 charts 1 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡